Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

1.

Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated to rheumatoid arthritis.

Yamamoto M, Yokoyama Y, Shimizu Y, Yajima H, Sakurai N, Suzuki C, Naishiro Y, Takahashi H.

Mod Rheumatol. 2015 Jul 3:1-7. [Epub ahead of print] No abstract available.

PMID:
26140465
4.

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.

Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R.

Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis-2014-205847. doi: 10.1136/annrheumdis-2014-205847. [Epub ahead of print]

5.

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.

Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, Vlahos B, Hammond C, Bukowski J, Li H, Schulman SL, Raber S, Zuckerman A, Isaacs JD.

Arthritis Res Ther. 2015 Apr 6;17:95. doi: 10.1186/s13075-015-0612-7.

6.

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.

Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd.

Ann Rheum Dis. 2015 Mar 20. pii: annrheumdis-2014-207191. doi: 10.1136/annrheumdis-2014-207191. [Epub ahead of print]

7.

Super-enhancers delineate disease-associated regulatory nodes in T cells.

Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker SC, Erdos MR, Davis SR, Roychoudhuri R, Restifo NP, Gadina M, Tang Z, Ruan Y, Collins FS, Sartorelli V, O'Shea JJ.

Nature. 2015 Apr 23;520(7548):558-62. doi: 10.1038/nature14154. Epub 2015 Feb 16.

PMID:
25686607
8.

Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis.

Tanaka Y, Zwillich SH.

Mod Rheumatol. 2015 Mar 12:1-2. [Epub ahead of print] No abstract available.

PMID:
25671402
9.

Emerging drugs for the treatment of axial and peripheral spondyloarthritis.

Braun J, Kiltz U, Heldmann F, Baraliakos X.

Expert Opin Emerg Drugs. 2015 Mar;20(1):1-14. doi: 10.1517/14728214.2015.993378. Epub 2015 Jan 9.

PMID:
25575936
10.

Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.

Nishimura K, Saegusa J, Matsuki F, Akashi K, Kageyama G, Morinobu A.

Arthritis Rheumatol. 2015 Apr;67(4):893-902. doi: 10.1002/art.39007.

PMID:
25545152
11.

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S.

Mod Rheumatol. 2015 Jul;25(4):514-21. doi: 10.3109/14397595.2014.995875.

PMID:
25496464
12.

Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety.

Meier FM, McInnes IB.

Best Pract Res Clin Rheumatol. 2014 Aug;28(4):605-24. doi: 10.1016/j.berh.2014.10.017. Epub 2014 Nov 21. Review.

PMID:
25481553
13.

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.

Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB.

Arthritis Rheumatol. 2015 Mar;67(3):616-25. doi: 10.1002/art.38974.

PMID:
25470338
14.
15.

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS.

Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14.

16.

New treatments for inflammatory rheumatic disease.

Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA.

Immunol Res. 2014 Dec;60(2-3):277-88. doi: 10.1007/s12026-014-8565-5.

PMID:
25381481
17.

Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.

Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ.

Arthritis Rheumatol. 2015 Jan;67(1):117-27. doi: 10.1002/art.38894. Review.

PMID:
25303044
18.

Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.

Lundquist LM, Cole SW, Sikes ML.

World J Orthop. 2014 Sep 18;5(4):504-11. doi: 10.5312/wjo.v5.i4.504. eCollection 2014 Sep 18. Review.

19.

Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.

Malemud CJ, Blumenthal DE.

World J Orthop. 2014 Sep 18;5(4):496-503. doi: 10.5312/wjo.v5.i4.496. eCollection 2014 Sep 18. Review.

20.

Tofacitinib versus methotrexate in rheumatoid arthritis.

Yuan K, Chen J, Xu A.

N Engl J Med. 2014 Sep 18;371(12):1163-4. doi: 10.1056/NEJMc1408607#SA2. No abstract available.

PMID:
25229928
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk